Updated
Updated · CNBC · Nov 17
Isomorphic Labs Raises $5 Billion Series C as AI Drug Discovery Funding Hits $23.2 Billion
Updated
Updated · CNBC · Nov 17

Isomorphic Labs Raises $5 Billion Series C as AI Drug Discovery Funding Hits $23.2 Billion

3 articles · Updated · CNBC · Nov 17

Summary

  • $5 billion in new funding will let Isomorphic Labs expand its AI drug-design engine, build foundational biology models and push its first therapeutic programs toward clinical trials.
  • Greenoaks and Sequoia co-led the Series C, with Andreessen Horowitz and Alphabet also investing, in one of the sector's biggest rounds just months after Isomorphic raised a $2.1 billion Series B in May.
  • Demis Hassabis has led Isomorphic since it spun out of DeepMind in 2021, and the raise comes about three-and-a-half months after he stepped back as CEO of Google's AI lab.
  • Drug-discovery startups have pulled in a record $23.2 billion in 2026 as AI enthusiasm spreads, with Anthropic launching a program in June and OpenAI partnering Novo Nordisk in April.

Insights

Can a $5 billion AI gamble truly solve the 90 percent failure rate of modern drug development?
With tech giants flooding biotech, are we witnessing the end of traditional pharma R&D as we know it?

$50 Billion Bet: Isomorphic Labs, AI Drug Discovery’s Funding Frenzy, and the Coming Clinical Reality Check

Overview

In 2026, Isomorphic Labs rapidly became a leader in AI-driven drug discovery, raising $7.7 billion in under two years, including a $5 billion Series C round that valued the company at $50 billion—far above industry peers. This surge was fueled by investors viewing Isomorphic as a foundational technology provider, not just a biotech startup, and was validated by major partnerships with Novartis, Eli Lilly, and Johnson & Johnson. However, while Isomorphic’s AI platform IsoDDE outperformed rivals in early-stage predictions, the sector faces challenges: critical safety data remains siloed, regulatory frameworks lack clear compliance steps, and the main bottleneck has shifted downstream to clinical trials, creating both high expectations and significant risks for future success.

...